Skip to content
2000
Volume 21, Issue 5
  • ISSN: 1568-0096
  • E-ISSN: 1873-5576

Abstract

Head and neck squamous cell carcinoma (HNSCC) continues to be a global public health burden even after a tremendous development in its treatment. It is a heterogeneous cancer of upper aero-digestive tract. The contemporary strategy to treat cancer is the use of anticancer drugs against proteins possessing abnormal expression. Targeted chemotherapy was found successful in HNSCC, but, there is still a stagnant improvement in the survival rates and high recurrence rates due to undesirable chemotherapy reactions, non-specificity of drugs, resistance against drugs and drug toxicity on non-cancerous tissues and cells. Various extensive studies lead to the identification of drug targets capable to treat HNSCC effectively. The current review article gives an insight into these promising anticancer targets along with knowledge of drugs under various phases of development. In addition, new potential targets that are not yet explored against HNSCC are also described. We believe that exploring and developing drugs against these targets might prove beneficial in treating HNSCC.

Loading

Article metrics loading...

/content/journals/ccdt/10.2174/1568009620666201229120332
2021-05-01
2025-09-02
Loading full text...

Full text loading...

/content/journals/ccdt/10.2174/1568009620666201229120332
Loading

  • Article Type:
    Review Article
Keyword(s): drug target; EGFR; HNSCC; MEK1; PIK3CA; RAC1; S6K2
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test